AB0203 EXPRESSION LEVELS OF SELECTED GENES CAN PREDICT THE INDIVIDUAL RHEUMATOID ARTHRITIS PATIENT RESPONSE TO TUMOR NECROSIS FACTOR ALPHA BLOCKER TREATMENT
Background: Rheumatoid arthritis (RA) patients have many therapeutic options. However, there are limited tools to predict the individual patient's response to therapy. The Genefron personal diagnostic kit (IFR 300) has been developed based on analysis of large databases to select interferon stimulated gene (ISG) expressions which could predict response to a biologic agent Objectives: This study aims to evaluate the ability of the Genefron diagnostic kit to predict the individual RA patient response to TNFα blockers. Methods: Two separate analyses were performed, one retrospective and one prospective analysis. The response of 61 RA patients reported in 2 published data sets was analyzed retrospectively utilizing the Genefron kit. In addition, 18 patients with RA were assessed prospectively, before and 3 months after starting treatment with a TNFα blocker. Clinical assessment included swollen and tender joint counts, patient and physician assessments of disease activity. Patients' blood samples were obtained before administration of the TNFα blocker and were analyzed utilizing the Genefron diagnostic kit which measures expression levels of selected genes by quantitative real time PCR. Results: Genefron kit analysis of retrospective data correctly predicted the response to a TNFα blocker in 53 of 61 RA patients (accuracy -86.8%). In the prospective analysis 6 patients achieved a moderate EULAR response, 6 achieved a good EULAR response and 6 did not respond. According to the EULAR moderate response, the Genefron diagnostic kit predicted the response correctly in 16 of 18 patients (accuracy-89%, sensitivity -100%, specificity -67%). According to the EULAR good response, the kit predicted the response correctly in 15 of 18 patients (accuracy -83.3%, sensitivity -100%, specificity -75%). Background: Atherosclerotic cardiovascular disease (ASCVD) is the main mortality cause in patients with rheumatoid arthritis (RA) (1). It has been proven that the carotid intima-media thickness (CIMT) measured with carotid duplex ultrasonography (US) is an important ASCVD predictor with a measurement ≥0.9 mm (2-4). Objectives: To characterize the disease factors related with abnormal carotid duplex US findings in Mexican mestizo patients with RA. Methods: In a cross-sectional setting, we enrolled consecutive RA patients. Patients with overlap syndromes, personal history of ASCVD, dyslipidemia and previous use of any statin were excluded. A board-certified radiologist performed a bilateral carotid duplex US to all patients. Abnormal CIMT was defined as ≥0.9 mm (hypertrophy ≥0.9 -1.2 mm and carotid plaque ≥1.2 mm). A clinical history and blood tests were performed at the time of the patient's visit. Disease activity was measured with Disease Activity Score using 28 joints-C-reactive protein (DAS28-CRP). Results: We enrolled 57 patients. Demographic characteristics are shown in table 1. A total of 30 (52.2%) patients had an abnormal CIMT. US findings are shown in table 2. A significant correlation between abnormal CIMT and RA disease duration (p=0.04), as well as between the former and anti-cyclic citrullinated peptide antibodies (ACPA) positivity (p=0.033) was found. Conclusions: There is a strong relationship between CIMT and the chronic inflammatory process of RA, as well as ACPA positivity. These results might be influenced by the high mean disease duration of our patients. Prospective studies that evaluate CIMT among disease duration intervals are necessary to support these findings. Table 2 . CIMT alterations were more common in Group 2 (66.7%) than in Group 1 (38.7%), with statistical significance (p=0.013). Presence of carotid plaque was more common in Group 2 (27.5%) than in Group 1 (16.1%), shown clinical relevance, although did not shown statistical significance (p=0.18). Background: Interleukin-17 (IL-17) and IL-17-induced CC-chemokine ligand 20 (CCL20) are increasingly implicated in the pathogenesis of rheumatoid arthritis (RA). A correlation has been reported to exist between serum levels of IL-17 and CCL20 and the disease activity following biologic treatment [1] . However, such an effect has not been universally demonstrated [2] . Objectives: The aim of the present study was to investigate if serum IL-17 and CCL20 reflect activity of the disease and whether they could be of prognostic value for predicting therapeutic response to biologic therapy in RA. Methods: Thirty RA patients qualified to receive biologic treatment were prospectively assessed before and 12 weeks of therapy with either TNFα inhibitors or anti-IL-6 receptor antibodies. Serum concentrations of IL-17 and CCL20 were measured with high sensitivity ELISA with estimated detection levels 0.01 pg/ml and 0.47 pg/ml, respectively. Successful response to therapy was defined by the EULAR criteria. Results: The patient baseline characteristics were summarized in Table 1 . Twelve weeks of biologic treatment resulted in a significant improvement in the majority of the patients with only 2 patients (7%) identified as non-responders. The favorable response to therapy was reflected both by clinical and standard biochemical criteria (Table 2) . However, the mean serum concentrations of IL-17 and CCL20 did not change significantly over the course of therapy and they did not correlate with the disease activity, response to therapy, the type of biologic intervention and other medication used. Serum IL-17 and CCL20 levels showed no correlation with DAS28, and standard inflammatory markers. Conclusions: Serum levels of IL-17 and CCL20 did not parallel changes in the clinical status and standard biochemical parameters in patients undergoing biologic treatment for RA. Thus, the measurement of IL-17 and CCL20 in serum does not seem to provide additional information that would help to monitor the response to biologic treatment in RA more effectively. 
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